

DAFTAR PUSTAKA

1. Yap YY, Hassan S, Chan M, Choo PK RM. Epstein Barr Virus DNA Detection in the Diagnosis of Nasopharyngeal Carcinoma. *Am Acad Otolaryngol Neck Surg Found*. 2007;136(6):986-91.
2. Yu MC, Yuan JM. Epidemiology of Nasopharyngeal Carcinoma. *Cancer Biol*. 2002;12(02):421-9.
3. Ma J, Cao S. Nasopharyngeal Cancer Multidisciplinary Management. Dalam: Lu JJ, Cooper JS, Lee AWM, editor (penyunting). *The Epidemiology of Nasopharyngeal Carcinoma*. Berlin: Springer; 2010. p.1-7.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2018;68(6):394-424.
5. Ayee R, Ofori MEO, Tagoe EA, Languon S, Searyoh K, Armooh L et al. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana. *MDPI*. 2020;12(5):1-9.
6. Ganguly. Epidemiological and Etiological Factors Associated with nasopharyngeal Carcinoma. *Mathur Indian Counc Med Res New Delhi*. 2003;33(9):33(9).
7. Cheng H. Nasopharyngeal Cancer and the Southeast Asian Patient. *Am Fam Physician*. 2001;63(9):1776-82.
8. Carioli G, Negri E, Kawakita D, Garavello W, Vecchia CL MM. Global Trends in Nasopharyngeal Cancer Mortality Since 1970 and Predictions for 2020: Focus on Low-Risk Areas. *Int J Cancer*. 2017;140(10):2256-64.
9. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani, Gondhowiardjo S et al. Nasopharyngeal Carcinoma in Indonesia: Epidemiology, Incidence, Signs, and Symptoms at Presentation. *Chin J Cancer*. 2012;31(4):185-96.
10. Rahman S, Kurniawan H, Budiman BJ, Yerizel E, Bachtiar H. Evaluation of Serum IgA Antibodies to Epstein-Barr Virus Early and Viral Capsid Antigens in Nasopharyngeal Carcinoma. *KnE Eng*. 2019;1(2):275-83.
11. Hsu WL, Yu KJ, Chien YC, Chiang CJ, Cheng YJ, Chen JY et al. Familial Tendency and Risk of Nasopharyngeal Carcinoma in Taiwan: Effects of Covariates on Risk. *Am J Epidemiol*. 2011;173(3):292-9.
12. Tao Q, Chan ATC. Nasopharyngeal Carcinoma : Molecular Pathogenesis and Therapeutic Developments. *Expert Rev Mol Med*. 2007;9(12):1-24.
13. Wen W, Mai SJ, Lin HX, Zhang MY, Huang JL, Hua X et al. Identification of Two MicroRNA Signatures in Whole Blood as Novel Biomarkers For Diagnosis of Nasopharyngeal Carcinoma. *J Transl Med*. 2019;17(1):1-13.
14. Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM. Therapeutic Implications of Epstein – Barr Virus Infection For The Treatment Of Nasopharyngeal Carcinoma. *Dove Press J*. 2014;10(9):721-36.
15. Tsang CM, Tsao SW. The Role of Epstein-Barr virus Infection in The Pathogenesis of Nasopharyngeal Carcinoma. *Virol Sin*. 2015;30(2):107-21.
16. Traub NR. Epstein – Barr Virus in The Pathogenesis of NPC. *Elsevier Sci*. 2002;12(02):431-41.
17. Lung ML, Cheung AKL, Ko JMY, Lung HL, Cheng Y, Dai W. The Interplay

- of Host Genetic Factors and Epstein-Barr Virus in The Development of Nasopharyngeal Carcinoma. *Chin J Cancer*. 2014;33(11):566-8.
18. Lao DT, Truong KP, Ai T, Le H. Study of Epstein-Barr Virus Nuclear Antigen (EBNA-1) Variations: V- val Type Preferentially Exists In Biopsies of Nasopharyngeal Carcinoma From Vietnamese Patients. *Iran J Ped Hematol Oncol*. 2018;8(2):75-86.
 19. Borthakur P, Katakai K, Keppen C, Khamo V, Medhi S DM. Expression of Epstein Barr Virus Encoded EBNA1 and LMP1 Oncoproteins in Nasopharyngeal Carcinomas From Northeast India. *Asian Pacific J Cancer Prev*. 2016;17(7):3411-6.
 20. Tsao SW, Yip YL, Tsang CM, Lau VMY, Zhang G, Lo KW. Etiological Factors of Nasopharyngeal Carcinoma. *Oral Oncol*. 2014;50(5):330-8.
 21. He JQ, Sun L, He J, Zhu C, Lei J, He Q et al. The Pathogenesis and Therapeutics of Nasopharyngeal Carcinoma The Classification of Nasopharyngeal Carcinoma The Causes Carcinoma of Nasopharyngeal. *Heal Sci J*. 2019;13(2):1-7.
 22. Argirion I, Zarins KR, Ruterbusch JJ, Vatanasapt P, Sriplung H, Seymour EK et al. Increasing incidence of Epstein-Barr virus-related nasopharyngeal carcinoma in the United States. *Cancer*. 2019;5(1):1-10.
 23. Asante DB, Asmah RH, Adjei AA, Kyei F, Simpong DL, Brown CA, Gyasi RK. Detection of Human Papillomavirus Genotypes and Epstein Barr Virus in Nasopharyngeal Carcinomas at the Korle-Bu Teaching Hospital, Ghana. *Sci World J*. 2017;(3):1-9.
 24. Rahman S. Hubungan DNA Virus Epstein Barr, Alel HLA-DRB1 dan Polimorfisme Gen CYP2E1 dengan Kejadian Karsinoma Nasofaring pada Etnik Minangkabau. (Disertasi). Padang: Universitas Andalas; 2019.
 25. Adham M, Grejjer AE, Verkuijlen SAWM, Juwana H, Fleig S, Rachmadi L et al. Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients Before and After Treatment. *Clin Cancer Res*. 2013;19(8):2175-86.
 26. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal Carcinoma. *Ann Oncol*. 2002;13(7):1007-15.
 27. Hutajulu SH, Indrasari SR, Indrawati LPL, Harijadi A, Duin S, Haryana SM, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. *Mol Cancer*. 2011;10(48):1-9.
 28. Lao RD, Nguyen DH, Nguyen TM LT. Molecular Screening for Epstein Barr Virus (EBV): Detection of Genomic EBNA-1, EBNA-2, LMP-1, LMP-2 Among Vietnamese Patients with Nasopharyngeal Brush Samples. *Asian Pacific J Cancer Prev*. 2017;18(6):1675-9.
 29. Zhang PF, Zheng XH, Li XZ, Tian T, Zhang SD, Hu YZ et al. Nasopharyngeal Brushing: a Convenient and Feasible Sampling Method for Nucleic Acid-Based Nasopharyngeal Carcinoma Research. *Cancer Commun (London, England)*. 2018;38(8):1-10.
 30. Wang J, Luo Y, Bi P, Lu J, Wang F, Liu X et al. Mechanisms of Epstein-Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma. *Cancer Med*. 2020;12(5):1-11.
 31. Pfisfer DG, Ang KK, Brizel DM, Busse DM, Cmelak AJ, Dunphy F, et al, editor. National Comprehensive Cancer Network (NCCN). Philadelphia:

- Plymouth Meeting; 2020
32. Gu AD, Mo HY, Bei JX, Xie YB, Chen LZ, Feng QS et al. Evaluation of Antibodies Against Different Epstein Barr Virus Nuclear Antigen 1 Peptides in Diagnosis of Nasopharyngeal Carcinoma. *Clin Vaccine Immunol.* 2009;16(4):592-3.
 33. Lo YMD, Chan LYS, Lo KW, Leung SF, Zhang J, Chan ATC et al. Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients With Nasopharyngeal Carcinoma. *Cancer Res.* 1999;59(6):1188-91.
 34. Rozianty PD, Soehartono SH. Hubungan antara Kadar DNA EBV Plasma dengan Stadium Klinis KNF WHO Tipe 3. *Orli.* 2018;48(2):165-72.
 35. Yip TTC, Ngan RKC, Fong AHW, Law SCK. Application of Circulating Plasma/Serum EBV DNA in The Clinical Management of Nasopharyngeal Carcinoma. *Elsevier.* 2014;50(6):527-38.
 36. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal Carcinoma. *Lancet.* 2016;387 (5):1012-4.
 37. Cao SM, Simons MJ, Qian C. The Prevalence and Prevention of Nasopharyngeal Carcinoma in China. *Chin J Cancer.* 2011;30(2):114-9.
 38. Salehiniya H, Mohammadian M, Hafshejani AM, Mahdavi N. Nasopharyngeal Cancer in The World: Epidemiology, Incidence, Mortality and Factors. *World Cancer Res J.* 2018;5(1):1-8.
 39. Pitoyo AJ, Triwahyudi H. Dinamika Perkembangan Etnis di Indonesia dalam Konteks Persatuan Negara. *Populasi.* 2018;25(1):64-81.
 40. Hati PC. Dakwah Pada Masyarakat Minangkabau (Studi Kasus Pada Kaum Padri). *Islam Commun J.* 2018;3(1):105-20.
 41. Furusaka T, Tanaka A, Matsuda H, Hasegawa H, Asakawa T, Shigihara S. Cervical branch of the facial nerve approach for retrograde parotidectomy compared with anterograde parotidectomy. *Acta Otolaryngol.* 2014;134(11):1192-7.
 42. Sari JTY. Hubungan Alel Human Leukocyte Antigen A*11 Dengan Kejadian Karsinoma Nasofaring Pada Etnik Minangkabau di RSUP M. Djamil Padang. (Tesis). Padang: Universitas Andalas;2019
 43. Brennan B. Nasopharyngeal Carcinoma. *Orphanet J Rare Dis.* 2006;1(23):1-5.
 44. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. *Int J Cancer.* 2015;136(5):359-86.
 45. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early Detection of Nasopharyngeal Carcinoma. *Int J Otolaryngol.* 2011;2011(3):1-6.
 46. Munir D. Peran HLA pada Karsinoma Nasofaring. *Maj Kedokt Nusant.* 2010;39(3):324-30.
 47. Yenita AA. Korelasi antara Latent Membrane Protein-1 Virus Epstein-Barr dengan P53 pada Karsinoma Nasofaring (Penelitian Lanjutan). *J Kesehat Andalas.* 2012;1(1):4-6.
 48. Faiza S, Sukri R, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *Jurnal Kesehatan Andalas.* 2013;5(1):90-6.
 49. Diniati A, Ade WFW, Harianto. Distribusi keganasan nasofaring berdasarkan pemeriksaan histopatologi pada rumah sakit di kota pekanbaru

- tahun 2009-2013. *Jom Fk.* 2016;3(1):1-18.
50. Dawolo AP, Utama DS, Kasim BI. Profil Klinis Karsinoma Nasofaring di Departemen THTKL RSUP Dr . Mohammad Hoesin Palembang Tahun 2014-2015. *Maj Kedokt Sriwij.* 2017;2015(1):1-9.
 51. Suta PDD, Saputra KAD, Sutanegara SWD. Profil Penderita Kanker Nasofaring Di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Januari – Desember Tahun 2014. *E-Jurnal Med.* 2019;8(2):1-14.
 52. Naomi SM, Dewi YA, Agustina H. Association Between Histopathological Grading and Clinical Staging in Nasopharyngeal Carcinoma. *J Med Heal.* 2018;2(2):730-7.
 53. Astantang A. Karakteristik Penderita Karsinoma Nasofaring pada Pasien Rawat Jalan di Rumah Sakit Umum Pusat DR. Wahidin Sudirohusodo Periode Juni 2016-Juni 2017. (Tesis). Universitas Hasanuddin; 2017.
 54. Barnes L, Eveson JW, Reichart P SD. World Health Organization Classification of Tumours Pathology & Genetics Head and Neck Tumours IARC WHO Classification Head and Neck Tumours. In: World Health Organization. France: IARC Press; 2005. p. 81-97.
 55. Franchi Alessandro PA and E-MSK. Nasopharynx and Oropharynx. In: Cardesa Antonio, Slootweg Pieter J, Gale Nina FA, ed. *Pathology of the Head and Neck. Second.* Italy: Springer; 2016. p. 295-331.
 56. Wenig Bruce M. Non Neoplastic Lesions of The Sinonasal Tract. In: *Atlas of Head and Neck Pathology.* 3rd ed. New York: Elsevier; 2016. p. 24-26.
 57. Ondrey FG, Wright SK. Neoplasma of the Nasopharynx. Dalam : Snow JB, Ballenger JJ, editor (penyunting). *Ballenger's Otorhinolaryngology Head and Neck Surgery.* Edisi ke-16. Spain: BC Decker; 2009. p.1392-407.
 58. Cheesman AD. Pharynx. Dalam: Brennan PA, Mahadevan V, Evans BT, editor (penyunting). *Clinical Head and Neck Anatomy for Surgeons.* New York: CRC Press Taylor & Francis Group; 2016. p. 181-93.
 59. Zeng YX, Zeng MS. Pathogenesis and Etiology of Nasopharyngeal Carcinoma. Dalam: Lu JJ, Cooper JS, Lee AWM., editor (penyunting). *Nasopharyngeal Cancer Multidisciplinary Management.* Germany: Springer; 2010. p. 9-25.
 60. Chattopadhyay NR, Das P, Chatterjee K, Choudhuri T. Higher Incidence of Nasopharyngeal Carcinoma in Some Regions in The World Confers For Interplay Between Genetic Factors and External Stimuli. *Drug Discov Ther.* 2017;11(4):170-80.
 61. Jia WH, Qin HD. Non Viral Environmental Risk Factors For Nasopharyngeal Carcinoma : A Systematic Review. *Semin Cancer Biol.* 2012;22(2):117-26.
 62. Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, et al. Evaluation of Nonviral Risk Factors For Nasopharyngeal Carcinoma in a High Risk Population of Southern China. *Publ Int Union Against Cancer.* 2009;124(1):2942-7.
 63. Bosetti C, Mclaughlin JK, Tarone RE, Pira E, Vecchia C. Formaldehyde and Cancer Risk : a Quantitative Review of Cohort Studies Through 2006. *Ann Oncol.* 2008;19(1):29-43.
 64. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality From Solid Cancers among Workers in Formaldehyde Industries. *Am J Epidemiol.*

- 2004;159(12):1117-30.
65. Chang ET, Adami HO. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2006;15(10):1765-78.
 66. Thompson MP, Kurzrock R. Epstein-Barr Virus and Cancer. *Clinical Cancer Research.* 2004;10(713):803-21.
 67. Niedobitek G. Epstein Barr Virus Infection in The Pathogenesis of Nasopharyngeal Carcinoma. *J Clin Pathol.* 2000;53:248-254.
 68. Minarovits JNH. Current Trends and Alternative Scenarios in EBV Research. *Methods Mol Biol.* 2017;1532(5):1-32.
 69. Wei WI, Chua DTT. Nasopharyngeal Carcinoma. Dalam: Johnson Jonas JT, Rosen CA, editor (penyunting). *Bailey's Head and Neck Surgery Otolaryngology.* Fifth. China: Lippincot Williams & Wilkins; 2014. p. 1875-97.
 70. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early Detection of Nasopharyngeal Carcinoma. *Int J of Otolaryngology.* 2011;2011(3):1-6.
 71. Lo SS, Lu JJ. Natural History, Presenting Symptoms, and Diagnosis of Nasopharyngeal Carcinoma. Dalam: Lu JJ, Cooper JS, Lee AWM, editor. *Nasopharyngeal Cancer Multidisciplinary Management.* Berlin: Springer Berlin Heidelberg; 2010.41-51.
 72. Ondrey FG, Wright SK. Neoplasms of the Nasopharynx. Dalam: Snow JB, Ballenger JJ, editor. *Ballenger's Otorhinolaryngology Head and Neck Surgery.* Edisi-16. Spain: BC Decker; 2003. p. 1392-407.
 73. Lee AVM, Lydiatt WM, Colevas D, Glastonbury C. Nasopharynx. In: *American Joint Committee on Cancer Cancer Staging Manual.* Eighth. Chicago: Springer; 2017. p. 103-111.
 74. Lin JC. Prognostic Factor in Nasopharyngeal Cancer. Dalam: Lu JJ, Cooper JS, Lee AWM, editor. *Nasopharyngeal Cancer Multidisciplinary Management.* Berlin: Springer Berlin Heidelberg; 2010.95-136.
 75. Wei WI, Kwong DLW. Current Management Strategy of Nasopharyngeal Carcinoma. *Clin Exp Otorhinolaryngol.* 2010;3(1):1-12.
 76. Arthur C, Ruan H, Wang X, Zhou XJ, Liu S, Zhou P, et al. Retrospective Analysis of 5-Year Survival Rate of Nasopharyngeal Carcinoma: Correlation with Clinical Features and Prognosis. *J Cancer Res Ther Oncol.* 2019;1(1):1-5.
 77. Murray PG, Young LS, Murray PG. Epstein – Barr virus infection : basis of malignancy and potential for therapy. *Expert Rev Mol Med.* 2001;44(0):1-20.
 78. Hudnall SD. Epstein – Barr Virus : Pathogenesis and Host Immune Response. Dalam: Hudnall SD, Editor. *Viruses Hum Cancer.* New York: Springer; 2014. 7-24.
 79. Chou J, Lin YC, Kim J, You L, Xu Z, He B et al. Nasopharyngeal Carcinoma - Review of the Molecular Mechanisms of Tumorigenesis. *Head & Neck.* 2008;1(0):946-963.
 80. Korcum AF, Ozyar E, Ayhan A. Epstein-Barr Virus Genes and Nasopharyngeal Cancer. *Turkish J Cancer.* 2006;36(3):97-107.
 81. Tsang CM, Deng W, Yip YL, Zeng MS, Lo KW, Tsao SW. Epstein - Barr Virus Infection and Persistence in Nasopharyngeal Epithelial Cells. *Chin J Cancer.* 2014;33(11):549-55.

82. Hausen HZ. Gammaherpesvirinae (Lymphocryptoviruses). Dalam: Hausen HZ. Infection Causing Human Cancer. Germany: Wiley-VCH; 2006. p. 65-117.
83. Chen C, Li D, Guo N. Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: Implications for therapy of EBV associated tumors. *Cancer Biol Ther.* 2009;8(11):987-95.
84. Münz C. Epstein-Barr virus nuclear antigen 1: From immunologically invisible to a promising T cell target. *J Exp Med.* 2004;199(10):1301-4.
85. Yin H, Qu J, Peng Q, Gan R. Molecular Mechanisms of EBV Driven Cell Cycle Progression and Oncogenesis. *Med Microbiol Immunol.* 2018;11(0):1-11.
86. Frappier L. The Epstein Barr Virus EBNA1 Protein. *Scientifica (Cairo).* 2012;2012(10):1-15.
87. Frappier L. Role of EBNA1 in NPC tumourigenesis. *Semin Cancer Biol.* 2012;22(2):154-61.
88. Rivera-Soto R, Damania B. Modulation of Angiogenic Processes by the Human Gammaherpesviruses, Epstein–Barr Virus and Kaposi’s Sarcoma-Associated Herpesvirus. *Front Microbiol.* 2019;10(7):1-24.
89. Mungerson MS, Ikeda M, Lev L, Longnecker R, Portis T. Identification of Latent Membrane Protein 2A (LMP2A) Specific Targets for Treatment and Eradication of Epstein Barr Virus (EBV) -Associated Diseases. *J Antimicrob Chemother.* 2003;52(7):152-4.
90. Krishna SM, James S, Kattoor J, Balaram P. Serum EBV DNA as a Biomarker in Primary Nasopharyngeal Carcinoma of Indian Origin. *Jpn J Clin Oncol.* 2004;34(6):307-11.
91. Tiwawech D, Ng PSP. Detection of IgA Antibody Against Epstein-Barr Virus Nuclear Antigen 1 in Nasopharyngeal Carcinoma Patients by ELISA. 2008;28 (2):83-92.
92. Smriti. M. Krishna, M.Phil., Susan James, M. D. STT, Jayashree Kattoor, M.D., Prabha Balaram PD. Primary Nasopharyngeal Cancer of Indian Origin and the Viral Link - A Preliminary Study. 2006;5(4):241-52.
93. Adam AA. Pathology of Nasopharyngeal Carcinoma in Sudanese Patients and its Association with Epstein-Barr Virus: A Report from a Single Center in Khartoum. *Adv Tumor Virol.* 2011;2(2011):1-6.
94. Geograph88. Klasifikasi Ras Manusia. 2016:1-2.
95. Naim A, Syahputra H. Kewarganegaraan, Suku Bangsa, Agama dan Bahasa Sehari-Hari Penduduk Indonesia. In: Badan Pusat Statistik. 2010.
96. Santos DJDS, Palomares NB, Normando D QC. Race Versus Ethnicity: Differing for Better Application. *Dental Press J Orthod.* 2010;15(3):121-4.
97. Sopiudin D, editor. Menggunakan Rumus Besar Sampel Secara Benar. Salemba Medika. Tiga. Jakarta; 2010:35-80.
98. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods.* 2001;25(4):402-8.
99. Edris A, Mohamed MA, Mohamed NS, Siddig EE. Molecular Detection of Epstein - Barr virus in Nasopharyngeal Carcinoma among Sudanese population. *Infect Agent Cancer.* 2016;11(1):1-5.
100. Munir D. Beberapa Aspek Karsinoma Nasofaring pada Suku Batak di Medan

- dan Sekitarnya. *Maj Kedokt Nusant.* 2006;39(3):221-4.
101. Zeng MS, Zeng YX. Pathogenesis and Etiology of Nasopharyngeal Carcinoma. Dalam: Lu JJ, Cooper JS, Lee AWM. *Nasopharyngeal Cancer Multidisciplinary Management.* Berlin: Springer Berlin Heidelberg; 2010. p. 9-25.
 102. Hsu WL, Chen JY, Chien YC, Liu MY, You SL, Hsu MW, et al. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: A 20-year follow-up study on 9,622 males without family history in Taiwan. *Cancer Epidemiol Biomarkers Prev.* 2009;18(4):1218-26.
 103. Prabowo I, Zuliyanto A, Setiamika M, Sudrajad H, Anggraini AH, Budiani DR, et al. the Relation of Ebna-1 and Egfr Expression Screening From Advanced Stage Undifferentiated Nasopharyngeal Cancer. *Int J Nasopharyngeal Carcinoma.* 2019;1(02):55-60.
 104. Peterson BR, Nelson BL. Nonkeratinizing Undifferentiated Nasopharyngeal Carcinoma. *Head Neck Pathol.* 2013;7(1):73-5.
 105. Hogskolan T, Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, et al. Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients : Options for Fiel. *J Clin Microbiol.* 2006;44(4):1459-67.
 106. Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling pathway: An update on molecular biomarkers. *Int J Cell Biol.* 2012;2012(12):1-10.
 107. Wu LEI, Li C, Pan LI. Nasopharyngeal carcinoma : A review of current updates. *Exp Ther Med.* 2017;15(4):3687-92.
 108. Lau HY, Leung CM, Chan YH, Lee AWM, Kwong DLW, Lung ML, et al. Secular trends of salted fish consumption and nasopharyngeal carcinoma: a multi-jurisdiction ecological study in 8 regions from 3 continents. *BMC Cancer.* 2013;13(1):1-11
 109. Yong SK, Ha TC, Yeo MCR, Gaborieau V, Mckay JD, Wee J. Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: A case-control study. *Chin J Cancer.* 2017;36(1):3-10.
 110. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day N. Preserved foods and nasopharyngeal carcinoma: A case-control study among singapore chinese. *Int J Cancer.* 1994;59(5):585-90.
 111. Friborg JT, Yuan JM, Wang R, Koh WP, Lee HP, Yu MC. A prospective study of tobacco and alcohol use as risk factors for pharyngeal carcinomas in Singapore Chinese. *Cancer.* 2007;109(6):1183-91.
 112. Long M, Fu Z, Li P, Nie Z. Cigarette smoking and the risk of nasopharyngeal carcinoma: A meta-analysis of epidemiological studies. *BMJ Open.* 2017;7(10):14-7.
 113. Saikia A, Raphael V, Shunyu N-B, Khonglah Y, Mishra J, Jitani AK, et al. Analysis of Epstein Barr Virus Encoded RNA Expression in Nasopharyngeal Carcinoma in North-Eastern India: A Chromogenic in Situ Hybridization Based Study. *Anal Epstein Barr Virus Encoded RNA Expr Nasopharyngeal Carcinoma North-Eastern India A Chromogenic Situ Hybrid Based Study.* 2016;28(87):267-74.
 114. Eissa S, Kassim SK, Imam M, Khalifa A. Correlation between EBV DNA

- and rearrangement and expression of bcl-2 gene in aggressive non-Hodgkin's lymphoma. *IUBMB Life*. 1999;48(2):231-6.
116. Ruan Y, Hu W, Li W, Lu H, Gu H, Zhang Y, et al. Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy. *Biomed Res Int*. 2019;2019(5):1-9.
 117. Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lertbutsayanukul C. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. *Journal of Radiation Research*. 2017;58(4):509-16.
 118. Thomasini RL, Pereira DS, Pereira FSM, Mateo EC, Mota TN, Guimaraes GG, et al. Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. *PLoS One*. 2017;12(7):1-12.
 119. He SS, Wang Y, Bao Y, Cai XY, Yang XL, Chen DM et al. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study. *Cancer Med*. 2018;7(4):1110-7.
 120. Sugiyanto S, Aryati L, Kusumo FA, Hardianti MS. Link of Nasopharyngeal Carcinoma and Epstein-Barr Virus. *Biol Med Nat Prod Chem*. 2018;7(2):51-5.
 121. Cohen JI. Epstein Barr Virus Infection. *N Engl J Med*. 2000;343(7):481-92.
 122. Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, et al. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. *Front Oncol*. 2020;10(5):1-18.
 123. Xue WQ, He YQ, Liao XY, Li FF, Xu YF, Xu FH, et al. Decreased oral Epstein-Barr virus DNA loads in patients with nasopharyngeal carcinoma in Southern China: A case-control and a family-based study. *Cancer Med*. 2018;7(7):3453-64.
 124. Greijer AE, Stevens SJ, Verkuijlen SA, Cornelissen JJ, Brooimans, Verdonck LF, et al. Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients. *Clin Dev Immunol*. 2012;2012.
 125. Wagner HJ, Bein G, Bitsch A, Kirchner H. Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. *J Clin Microbiol*. 1992;30(11):2826-9.
 126. Chan KCA, Hung ECW, Woo JKS, Chan PKS, Leung SF, Lai FPT, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. *Cancer*. 2013;119(10):1838-44.
 127. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, et al. Comparison of Plasma Epstein-Barr Virus (EBV) DNA Levels and Serum EBV Immunoglobulin A/Virus Capsid Antigen Antibody Titers in Patients with Nasopharyngeal Carcinoma. *Am Cancer Soc*. 2004;100(6):1162-70.
 128. Zhou H, Liu Y, Wang C, Liu L, Wang H, Zhang Y, et al. Triptolide inhibits Epstein-Barr nuclear antigen 1 expression by increasing sensitivity of mitochondria apoptosis of nasopharyngeal carcinoma cells. *J Exp Clin Cancer Res*. 2018;37(1):1-17.

129. Sivachandran N, Cao JY, Frappier L. Epstein-Barr Virus Nuclear Antigen 1 Hijacks the Host Kinase CK2 To Disrupt PML Nuclear Bodies. *J Virol*. 2010;84(21):11113-23.
130. Saridakis V, Sheng Y, Sarkari F, Holowaty MN, Shire K, Nguyen T, et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1: Implications for EBV-mediated immortalization. *Mol Cell*. 2005;18(1):25-36
131. Kumar V, Abbas AK FN. Neoplasia. In: *Pathologic Basis of Disease*. ke-7. Philadelphia: Elsevier; 2005:309-13.
132. Noh KW, Park J, Joo EH, Lee EK, Choi EY, Kang MS. ERK2 phosphorylation of EBNA1 serine 383 residue is important for EBNA1-dependent transactivation. *Oncotarget*. 2016;7(18):25507-15.
133. Lo KW, To KF, Huang DP. Focus on Nasopharyngeal Carcinoma. *Focus (Madison)*. 2004;5(5):423-8.
134. Apcher S, Daskalogianni C, Manoury B FR. Epstein Barr Virus Encoded EBNA1 Interference With MHC Class I Antigen Presentation Reveals a Close Correlation Between mRNA Translation Initiation and Antigen Presentation. *PLoS Pathog*. 2010;6(10):1-14.
135. Jayalie VF, Paramitha MS, Jessica, Liu CA, Ramadianto AS, Trimartani, et al. Profile of Nasopharyngeal Carcinoma in Dr. Cipto Mangunkusumo National Hospital, 2010. *eJournal Kedokt Indones*. 2017;4(3):156-62.
136. Smatti MK, Yassine HM, AbuOdeh R, Almarawani A, Taleb SA, Althani AA, et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. *PLoS One*. 2017;12(12):1-20.
137. Chen Y, Zhao W, Lin L, Xiao X, Zhou X, Ming H, et al. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening. *PLoS One*. 2015;10(7):1-13.
138. Thuan LD, Tuan NHA, Kha ND, Hue TH, Giao HT, Chau NH, et al. Evaluation Of EBNA-1 (Epstein Barr Nuclear Antigen-1) Gene Prevalence In Nasopharyngeal Carcinoma In Vietnamese Patients. *J Sci Ho Chi Minh City Open Univ*. 2016;20(1):1-8.
139. Ferrari D, Codeca C, Bertuzzi C, Broggio F, Crepaldi F, Luciani A, et al. Role of Plasma EBV DNA Levels in Predicting Recurrence of Nasopharyngeal Carcinoma in a Western Population. *BMC Cancer*. 2012;12(208):1-7.
140. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of Plasma Epstein-Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma. *N Engl J Med*. 2004;350(24):2461-70.
141. Lin JC, Chen KY, Wang WY, Jan JS, Liang WM, Tsai CS, et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: Relationship to distant metastasis and survival. *J Clin Oncol*. 2001;19(10):2607-15.